667 related articles for article (PubMed ID: 30542351)
1. A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8
Matsuo K; Kitahata K; Kawabata F; Kamei M; Hara Y; Takamura S; Oiso N; Kawada A; Yoshie O; Nakayama T
Front Immunol; 2018; 9():2775. PubMed ID: 30542351
[TBL] [Abstract][Full Text] [Related]
2. Transcutaneous immunization with a highly active form of XCL1 as a vaccine adjuvant using a hydrophilic gel patch elicits long-term CD8
Kamei M; Matsuo K; Imanishi H; Hara Y; Quen YS; Kamiyama F; Oiso N; Kawada A; Okada N; Nakayama T
J Pharmacol Sci; 2020 Jul; 143(3):182-187. PubMed ID: 32386904
[TBL] [Abstract][Full Text] [Related]
3. The invariant natural killer T cell-mediated chemokine X-C motif chemokine ligand 1-X-C motif chemokine receptor 1 axis promotes allergic airway hyperresponsiveness by recruiting CD103
Woo YD; Koh J; Kang HR; Kim HY; Chung DH
J Allergy Clin Immunol; 2018 Dec; 142(6):1781-1792.e12. PubMed ID: 29474842
[TBL] [Abstract][Full Text] [Related]
4.
Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells.
Kamei M; Matsuo K; Yoshida Y; Shimada K; Otsuki M; Fujimoto N; Ishibashi M; Quan YS; Kamiyama F; Hara Y; Takamura S; Nakayama T
Int J Cancer; 2024 Jun; 154(12):2176-2188. PubMed ID: 38346928
[TBL] [Abstract][Full Text] [Related]
6. Anticancer effects of chemokine-directed antigen delivery to a cross-presenting dendritic cell subset with immune checkpoint blockade.
Mizumoto Y; Hemmi H; Katsuda M; Miyazawa M; Kitahata Y; Miyamoto A; Nakamori M; Ojima T; Matsuda K; Nakamura M; Hayata K; Fukuda-Ohta Y; Sugiyama M; Ohta T; Orimo T; Okura S; Sasaki I; Tamada K; Yamaue H; Kaisho T
Br J Cancer; 2020 Apr; 122(8):1185-1193. PubMed ID: 32066911
[TBL] [Abstract][Full Text] [Related]
7. Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus.
Fossum E; Grødeland G; Terhorst D; Tveita AA; Vikse E; Mjaaland S; Henri S; Malissen B; Bogen B
Eur J Immunol; 2015 Feb; 45(2):624-35. PubMed ID: 25410055
[TBL] [Abstract][Full Text] [Related]
8. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells.
Dorner BG; Dorner MB; Zhou X; Opitz C; Mora A; Güttler S; Hutloff A; Mages HW; Ranke K; Schaefer M; Jack RS; Henn V; Kroczek RA
Immunity; 2009 Nov; 31(5):823-33. PubMed ID: 19913446
[TBL] [Abstract][Full Text] [Related]
9. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
[TBL] [Abstract][Full Text] [Related]
10. The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.
Schmidt ST; Khadke S; Korsholm KS; Perrie Y; Rades T; Andersen P; Foged C; Christensen D
J Control Release; 2016 Oct; 239():107-17. PubMed ID: 27574990
[TBL] [Abstract][Full Text] [Related]
11. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells.
Crozat K; Guiton R; Contreras V; Feuillet V; Dutertre CA; Ventre E; Vu Manh TP; Baranek T; Storset AK; Marvel J; Boudinot P; Hosmalin A; Schwartz-Cornil I; Dalod M
J Exp Med; 2010 Jun; 207(6):1283-92. PubMed ID: 20479118
[TBL] [Abstract][Full Text] [Related]
12. Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control.
Botelho NK; Tschumi BO; Hubbell JA; Swartz MA; Donda A; Romero P
Front Immunol; 2019; 10():294. PubMed ID: 30863405
[TBL] [Abstract][Full Text] [Related]
13. Conservation of a chemokine system, XCR1 and its ligand, XCL1, between human and mice.
Yamazaki C; Miyamoto R; Hoshino K; Fukuda Y; Sasaki I; Saito M; Ishiguchi H; Yano T; Sugiyama T; Hemmi H; Tanaka T; Hamada E; Hirashima T; Amakawa R; Fukuhara S; Nomura S; Ito T; Kaisho T
Biochem Biophys Res Commun; 2010 Jul; 397(4):756-61. PubMed ID: 20541533
[TBL] [Abstract][Full Text] [Related]
14. Structure-Function Relationship of XCL1 Used for
Kroczek AL; Hartung E; Gurka S; Becker M; Reeg N; Mages HW; Voigt S; Freund C; Kroczek RA
Front Immunol; 2018; 9():2806. PubMed ID: 30619244
[TBL] [Abstract][Full Text] [Related]
15. [In Vivo Antigen Delivery to Dendritic Cells-A Novel Peptide Vaccine for Cancer Therapy].
Mizumoto Y; Katsuda M; Miyazawa M; Kitahata Y; Miyamoto A; Nakamori M; Ojima T; Matsuda K; Hemmi H; Tamada K; Kaisho T; Yamaue H
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1469-1471. PubMed ID: 30382048
[TBL] [Abstract][Full Text] [Related]
16. Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion.
Le Gall C; Cammarata A; de Haas L; Ramos-Tomillero I; Cuenca-Escalona J; Schouren K; Wijfjes Z; Becker AMD; Bödder J; Dölen Y; de Vries IJM; Figdor CG; Flórez-Grau G; Verdoes M
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35428705
[TBL] [Abstract][Full Text] [Related]
17. Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1+ dendritic cells induces potent antitumoral responses.
Terhorst D; Fossum E; Baranska A; Tamoutounour S; Malosse C; Garbani M; Braun R; Lechat E; Crameri R; Bogen B; Henri S; Malissen B
J Immunol; 2015 Jun; 194(12):5895-902. PubMed ID: 25941327
[TBL] [Abstract][Full Text] [Related]
18. Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node.
Kitano M; Yamazaki C; Takumi A; Ikeno T; Hemmi H; Takahashi N; Shimizu K; Fraser SE; Hoshino K; Kaisho T; Okada T
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):1044-9. PubMed ID: 26755602
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
20. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1.
Hartung E; Becker M; Bachem A; Reeg N; Jäkel A; Hutloff A; Weber H; Weise C; Giesecke C; Henn V; Gurka S; Anastassiadis K; Mages HW; Kroczek RA
J Immunol; 2015 Feb; 194(3):1069-79. PubMed ID: 25520399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
